2026: An AI-Driven Scientific Discovery Revolution – From New Drug Development to Physics

Artificial intelligence (AI) is no longer a story from science fiction movies. It's driving innovative changes in various fields of modern society, and especially showing remarkable potential in scientific research. AI's ability to analyze vast amounts of data and identify complex patterns is opening up new horizons that were previously unreachable by human scientists' intuition and experience. 2026 is expected to be an important year when this AI-driven scientific discovery revolution becomes a full-fledged reality, with notable advancements anticipated particularly in new drug development and protein structure prediction.

A New Horizon in New Drug Development: The Arrival of IsoDDE and AlphaFold 3

The efficiency of the new drug development process, which scientists have long dreamed of, is entering a completely new phase thanks to advancements in AI technology. In February 2026, Isomorphic Labs of Google DeepMind get industry attention by unveiling a new drug development engine called IsoDDE. This tool dramatically accelerates the discovery of potential new drug candidates by accurately analyzing interactions between molecules that were previously difficult to predict with conventional methods. A computational biologist at Columbia University even highly praised the emergence of IsoDDE, saying it's "as important a breakthrough as AlphaFold 4." This signifies that AI technology is moving beyond a mere supporting tool to perform a key role in the new drug development process.

IsoDDE demonstrates superior performance compared to existing methods or other AI models, such as Boltz-2, providing more efficient results than human capabilities or physics-based simulations when it comes to predicting complex molecular structures and drug binding affinity. This innovative technology is expected to significantly contribute to the treatment of intractable diseases such as cancer. In fact, Demis Hassabis announced at the World Economic Forum in Davos that the first cancer treatment designed by AI would enter Phase 1 clinical trials in early 2026. This is strong evidence that AI will actually play an important role in new drug development.

AlphaFold 3, the successor version of AlphaFold, is also showing remarkable progress. It can now predict molecular structures 50% more accurately than previous methods, achieving a performance that surpasses physics-based tools for the first time in the PoseBusters benchmark test. Its performance in predicting interactions between proteins and ligands has also improved by at least 50% compared to existing methods, providing valuable data both for studying various biological phenomena. Advancements in protein structure prediction technology are essential for understanding disease mechanisms and developing new therapies.

Industry Trust and Investment: A $3 Billion Partnership

Awareness of the potential of these AI technologies has led to impressive investments from the pharmaceutical industry. The partnership between Pfizer and Novartis, valued at a potential milestone payment of approximately $3 billion, demonstrates the industry's firm confidence in Google DeepMind's AI-driven drug development approach. This goes beyond simple technological cooperation and signals the beginning of a long-term partnership that can reshape the future paradigm of new drug development. Such investment will further accelerate research and development in the AI scientific discovery field and, in turn, offer new hope to patients.

Supporting Scientific Research: Google.org's $30 Million Investment

To increase the impact of AI technology on scientific discovery, Google subsidiary Google.org has launched a $30 million "AI for Science Impact Challenge." This program supports scientists worldwide in using AI to conduct innovative research, contributing to solving various scientific challenges. It focuses on using AI technology to solve problems that were previously insurmountable and creating new knowledge. This investment will play a important role in building collaboration between academia and industry and laying the foundation for the advancement of the AI scientific discovery field.

Looking to the Future: The Continuous Evolution of AI Scientific Discovery

2026 will be a important turning point that demonstrates the potential of AI-driven scientific discovery. However, this is just the beginning, and even more amazing advancements are expected in the future. AI will support innovative research both in various fields such as physics, chemistry, and biology. AI scientific discovery will move beyond simply analyzing data to setting new hypotheses, designing experiments, and helping interpret results, functioning as an intelligent research partner. However, along with the advancement of AI technology, various challenges, such as ethical issues, data bias, and job changes, must also be addressed. Overcoming these challenges and maximizing the potential of AI scientific discovery requires continued attention and effort. Specifically, strengthening AI ethics education and resolving data bias are important, as is close cooperation between scientists and AI experts. Preparations for job changes caused by AI technology advancements are also necessary. However, these challenges are full of potential to brighten the future of AI scientific discovery.

The AI scientific discovery revolution is opening a new era in scientific research and demonstrating the infinite possibilities that can enrich human lives. Through continuous research and development, proactive investment, and ethical considerations, we must create a bright future for AI scientific discovery.

---

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on your own judgment and responsibility.